FDA Safety Announcement Concerning Actos Use and Bladder Cancer Risk
The U.S. Food and Drug Administration, (FDA) released a safety announcement on September 17, 2010, that it is reviewing a 10-year epidemiological study to evaluate whether Actos (pioglitazone), is associated with an increased risk of bladder cancer. Actos, is a drug manufactured by Takeda to help control blood sugar levels in adults diagnosed with Type II diabetes mellitus. While the FDA has not made any conclusions about the study which is currently in its fifth year, it has indicated a statistical significance of increased bladder cancer risk in patients with prolonged use and/or higher dosage of Actos.
If you or a loved one is experiencing any side effects after using Actos or another drug to treat Type II diabetes, please contact Cohen & Malad, LLP to speak with one of our experienced product liability/personal injury attorneys to discuss your legal options and help you seek the compensation you deserve.